Trial · NCT01468207
Adverse events750
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 750
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Placebo (Period 1) | 1 | 152 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Adalimumab EW (Period 1) | 1 | 153 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Placebo/Adalimumab EW (Period 2) | 1 | 145 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Adalimumab EW/Placebo (Period 2) | 1 | 49 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Adalimumab EW/Adalimumab EOW (Period 2) | 0 | 48 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Adalimumab EW/Adalimumab EW (Period 2) | 2 | 48 | |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Placebo (Period 1) | 0 | 152 | |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Adalimumab EW (Period 1) | 0 | 153 | |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Placebo/Adalimumab EW (Period 2) | 2 | 145 | |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Adalimumab EW/Placebo (Period 2) | 1 | 49 | |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Adalimumab EW/Adalimumab EOW (Period 2) | 0 | 48 | |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Adalimumab EW/Adalimumab EW (Period 2) | 0 | 48 | |
| other | NEUTROPHILIA | Blood and lymphatic system disorders | Placebo (Period 1) | 1 | 152 | |
| other | NEUTROPHILIA | Blood and lymphatic system disorders | Adalimumab EW (Period 1) | 0 | 153 | |
| other | NEUTROPHILIA | Blood and lymphatic system disorders | Placebo/Adalimumab EW (Period 2) | 1 | 145 | |
| other | NEUTROPHILIA | Blood and lymphatic system disorders | Adalimumab EW/Placebo (Period 2) | 1 | 49 | |
| other | NEUTROPHILIA | Blood and lymphatic system disorders | Adalimumab EW/Adalimumab EOW (Period 2) | 0 | 48 | |
| other | NEUTROPHILIA | Blood and lymphatic system disorders | Adalimumab EW/Adalimumab EW (Period 2) | 0 | 48 | |
| other | VERTIGO | Ear and labyrinth disorders | Placebo (Period 1) | 0 | 152 | |
| other | VERTIGO | Ear and labyrinth disorders | Adalimumab EW (Period 1) | 0 | 153 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01468207/events